Back to top

UBS Sticks to Their Buy Rating for Resmed (RMD)

UBS analyst Marcus Curley maintained a Buy rating on Resmed today and set a price target of $335.00. The company’s shares opened today at $247.54. ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ResMed Inc. (RMD)